BioNTech vs Moderna
BNTX and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNTX and MRNA compare
BioNTech grew revenue faster over the last twelve months (4.3% versus −27.6% for Moderna).
BioNTech keeps more of each dollar of sales as profit, with a net margin of −39.6% compared with −141% at Moderna.
Moderna scores higher on the StockData Score (5 against 3 for BioNTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNTX | MRNA |
|---|---|---|
| Size and price | ||
| Market cap | – | $88.5B |
| Share price | $88.17 | $221.72 |
| Change, 1 year | −14.7% | 798% |
| Change, 5 years | −59.3% | −6.4% |
| Beta (5Y) | 0.82 | 1.11 |
| Employees | 500 | 4,700 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 39.7× |
| P/B | – | 13.1× |
| FCF yield | – | −1.4% |
| Fair value | – | $33.24 |
| Margin of safety | – | −567% |
| Growth | ||
| Revenue growth (TTM) | 4.3% (better) | −27.6% |
| Revenue growth, 5Y average | 42.9% (better) | 19.3% |
| Profitability | ||
| Gross margin | 77.6% (better) | 23.4% |
| Operating margin | −49.0% (better) | −149% |
| Net margin | −39.6% (better) | −141% |
| FCF margin | 9.8% (better) | −55.8% |
| Return on equity | – | −39.0% |
| Return on invested capital | – | −80.9% |
| Financial health | ||
| Debt / equity | – | 0.09 |
| Interest coverage | −20.1× | – |
| Current ratio | 7.54 (better) | 2.29 |
| Altman Z-score | – | 12.86 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 18.9% | 79.9% |
| Held by insiders | 58.1% | 5.6% |
| Insider net buying, 12 months | −$69.2M | −$64.6M (better) |
| Short interest, % of float | – | 8.2% |
Go deeper
- BNTX stock overview
- BNTX income statement
- BNTX valuation and score
- MRNA stock overview
- MRNA income statement
- MRNA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.